Research-grade Ipamorelin / CJC-1295 Blend 10 mg as a lyophilized powder in a glass vial. This blend contains 5 mg of Ipamorelin and 5 mg of CJC-1295 without DAC (Mod GRF 1-29), combined for synergistic research into growth hormone secretion.
Research Use Only: All products are intended exclusively for laboratory and scientific research. Not for human or veterinary use.
RESEARCH GRADE
Ipamorelin / CJC-1295 (no DAC) Blend 10 mg
Form
Lyophilized peptide powder
Content
5 mg Ipamorelin & 5 mg CJC-1295 (no DAC) per vial
Packaging
Glass vial with sterile closure
Storage
Store lyophilized at 2–8 °C (desiccated, protect from light)
Molecular formula
Mixture
Sequences
Ipamorelin: Aib-His-D-2-Nal-D-Phe-Lys-NH2
CJC-1295 (no DAC): Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2
CAS numbers
170851-70-4 (Ipamorelin)
863288-34-0 (CJC-1295 no DAC)
Tests
Ipamorelin / CJC-1295 Blend test
What is the Ipamorelin / CJC-1295 Blend?
This research blend combines two growth hormone (GH) secretagogues that act on different receptors. Ipamorelin is a selective agonist of the ghrelin/growth hormone secretagogue receptor (GHS-R). CJC-1295 (no DAC), also known as Modified GRF (1-29), is an analog of Growth Hormone Releasing Hormone (GHRH). They are combined to study the synergistic effect of activating both pathways simultaneously.
In laboratory studies, this blend is associated with research into:
- synergistic release of growth hormone (GH)
- simultaneous agonism of GHS-R and GHRH receptors
- pituitary function and endocrine signaling
- pulsatile GH secretion models
